The Use of Hydrazones for Biomedical Applications

The use of hydrazones presents an opportunity for enhancing drug delivery through site-specific drug release, including areas such as tumor tissue or thrombosis. Many researchers are experimenting on how to more efficiently form these hydrazones, specifically using heat and chemical catalysts. Hydrazones respond on the pH environment or are synthesized with particular functional groups of the hydrazone and are two of the many unique features that allow for their programmed drug release. Their flexibility allows them to be relevant in a diverse range of applications, from anti-inflammatory to anticancer to acting as a chelating agent. This review paper discusses efficient ways to optimize the properties of hydrazones and their utilization in various clinical applications, including anticancer, anti-inflammatory, the prevention of platelet aggregation, and roles as chelating agents.

[1]  Wen-en Zhao,et al.  Potent hydrazone derivatives targeting esophageal cancer cells. , 2018, European journal of medicinal chemistry.

[2]  Sulunay Parlar,et al.  Synthesis and evaluation of pyridinium‐hydrazone derivatives as potential antitumoral agents , 2018, Chemical biology & drug design.

[3]  I. Hussain,et al.  Exploring the Pharmacological Activities of Hydrazone Derivatives: A Review , 2017 .

[4]  Eric T. Kool,et al.  Oximes and Hydrazones in Bioconjugation: Mechanism and Catalysis. , 2017, Chemical reviews.

[5]  Rahul S. Kalhapure,et al.  Hydrazone linkages in pH responsive drug delivery systems , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  Guoquan Liu,et al.  A peptide-based pH-sensitive drug delivery system for targeted ablation of cancer cells. , 2015, Chemical communications.

[7]  Yu Cheng,et al.  Blood-brain barrier permeable gold nanoparticles: an efficient delivery platform for enhanced malignant glioma therapy and imaging. , 2014, Small.

[8]  J. Meyerhardt,et al.  Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. , 2014, The oncologist.

[9]  J. Bradner,et al.  Combined autophagy and proteasome inhibition , 2014, Autophagy.

[10]  M. Akhtar,et al.  A review exploring biological activities of hydrazones , 2014, Journal of pharmacy & bioallied sciences.

[11]  V. Saini,et al.  Therapeutic Potential of Hydrazones as Anti-Inflammatory Agents , 2014, International journal of medicinal chemistry.

[12]  M. Chung,et al.  Antiplatelet and Antithrombotic Activities of Non-Steroidal Anti-Inflammatory Drugs Containing an N-Acyl Hydrazone Subunit , 2014, Molecules.

[13]  Kun-Liang Guan,et al.  Autophagy regulation by nutrient signaling , 2013, Cell Research.

[14]  H. Abdel‐Aziz,et al.  Convenient synthesis, anti-inflammatory, analgesic and ulcerogenic activites of some new bis-hydrazones and pyrazole derivatives. , 2013, Acta Poloniae Pharmaceutica - Drug Research.

[15]  Pete Crisalli,et al.  Importance of ortho proton donors in catalysis of hydrazone formation. , 2013, Organic letters.

[16]  L. Lião,et al.  Design, Synthesis, Antinociceptive and Anti-Inflammatory Activities of Novel Piroxicam Analogues , 2012, Molecules.

[17]  S. Inoue,et al.  Cellular Delivery of Doxorubicin via pH-Controlled Hydrazone Linkage Using Multifunctional Nano Vehicle Based on Poly(β-L-Malic Acid) , 2012, International journal of molecular sciences.

[18]  E. Barreiro,et al.  Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition. , 2010, European journal of pharmacology.

[19]  A. Slawin,et al.  Syntheses, X-ray crystal structures, DNA binding, oxidative cleavage activities and antimicrobial studies of two Cu(II) hydrazone complexes , 2009 .

[20]  W. D. de Jong,et al.  Drug delivery and nanoparticles: Applications and hazards , 2008, International journal of nanomedicine.

[21]  D. Richardson,et al.  Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series. , 2008, Journal of medicinal chemistry.

[22]  Ş. Küçükgüzel,et al.  Biological activities of hydrazone derivatives. , 2007, Molecules.

[23]  R. Varma,et al.  Solid-state synthesis of heterocyclic hydrazones using microwaves under catalyst-free conditionsPresented, in part, at the 5th Electronic Conference on Synthetic Organic Chemistry, (ECSOC-5), 1–30 September 2001, E0014, http://www.mdpi.org/ecsoc-5.htm , 2002 .

[24]  D. Richardson,et al.  Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. , 1998, The Journal of laboratory and clinical medicine.

[25]  E. Barreiro,et al.  Synthesis and evaluation of analgesic, antiinflammatory and antiplatelet properties of new 2-pyridylarylhydrazone derivatives , 1998 .

[26]  P. Ponka,et al.  A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. , 1979, Biochimica et biophysica acta.

[27]  P. Ponka,et al.  Mobilization of iron from reticulocytes , 1979, FEBS letters.

[28]  S. Shibairo,et al.  Evaluation of Relative Competitive Ability and Fitness of Sorghum bicolor×Sorghum halepense and Sorghum bicolor×Sorghum sudanense F1 Hybrids , 2015 .